Treatment of relapsed/refractory severe aplastic anemia in children: Evidence‐based recommendations

Abstract Severe aplastic anemia (SAA) is a rare potentially fatal hematologic disorder. Although overall outcomes with treatment are excellent, there are variations in management approach, including differences in treatment between adult and pediatric patients. Certain aspects of treatment are under active investigation in clinical trials. Because of the rarity of the disease, some pediatric hematologists may have relatively limited experience with the complex management of SAA. The following recommendations reflect an up‐to‐date evidence‐based approach to the treatment of children with relapsed or refractory SAA.